Argenx SE logo

ARGX - Argenx SE Share Price

€240.8 1.8  0.8%

Last Trade - 11:35am

Sector
Healthcare
Size
Large Cap
Market Cap £8.80bn
Enterprise Value £7.41bn
Revenue £31.4m
Position in Universe 82nd / 847
Bullish
Bearish
Unlock ARGX Revenue
Momentum
Relative Strength (%)
1m -19.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
6.85 14.7 36.4 21.5 69.8 36.4 123.1 304.5 +39.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, argenxSE revenues decreased 48% to EUR36.4M. Net loss increasedfrom EUR163M to EUR528.9M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsForeign Exchange Gain/Loss–Non-Business decrease fromEUR6.1M (income) to EUR107M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ARGX
Graphical History

Revenue

ARGX Revenue Unlock ARGX Revenue

Net Income

ARGX Net Income Unlock ARGX Revenue

Normalised EPS

ARGX Normalised EPS Unlock ARGX Revenue

PE Ratio Range

ARGX PE Ratio Range Unlock ARGX Revenue

Dividend Yield Range

ARGX Dividend Yield Range Unlock ARGX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARGX EPS Forecasts Unlock ARGX Revenue
Profile Summary

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since July 10, 2014
No. of Shareholders: n/a
No. of Employees: 188
Sector Healthcare
Industry Biotechnology & Medical Research
Index BEL 20 , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 ,
Exchange Euronext - Brussels
Shares in Issue 42,761,528
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARGX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARGX
Upcoming Events for ARGX
Thursday 13th May, 2021
Q1 2021 argenx SE Earnings Release and Business Update
Frequently Asked Questions for argenx SE
What is the argenx SE share price?

As of 11:35am, shares in argenx SE are trading at €240.8, giving the company a market capitalisation of £8.80bn. This share price information is delayed by 15 minutes.

How has the argenx SE share price performed this year?

Shares in argenx SE are currently trading at €240.8 and the price has moved by 74.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the argenx SE price has moved by 57.51% over the past year.

What are the analyst and broker recommendations for argenx SE?

Of the analysts with advisory recommendations for argenx SE, there are there are currently 1 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for argenx SE is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will argenx SE next release its financial results?

argenx SE is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the argenx SE dividend yield?

argenx SE does not currently pay a dividend.

Does argenx SE pay a dividend?

argenx SE does not currently pay a dividend.

When does argenx SE next pay dividends?

argenx SE does not currently pay a dividend.

How do I buy argenx SE shares?

To buy shares in argenx SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of argenx SE?

Shares in argenx SE are currently trading at €240.8, giving the company a market capitalisation of £8.80bn.

Where are argenx SE shares listed? Where are argenx SE shares listed?

Here are the trading details for argenx SE:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: ARGX
What kind of share is argenx SE?

Based on an overall assessment of its quality, value and momentum, argenx SE is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a argenx SE share price forecast 2021?

Shares in argenx SE are currently priced at €240.8. At that level they are trading at 11.78% discount to the analyst consensus target price of 0.00.

Analysts covering argenx SE currently have a consensus Earnings Per Share (EPS) forecast of -12.708 for the next financial year.

How can I tell whether the argenx SE share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like argenx SE. Over the past six months, the relative strength of its shares against the market has been 17.26%. At the current price of €240.8, shares in argenx SE are trading at 5.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the argenx SE PE Ratio?

We were not able to find PE ratio data for argenx SE.

Who are the key directors of argenx SE?

argenx SE's management team is headed by:

Tim Van Hauwermeiren - CEO
Hans de Haard - CSO
Peter Verhaeghe - NEC
Werner Lanthaler - NVC
Eric Castaldi - CFO
Joseph deBethizy - NID
Pamela Klein - NID
Dirk Beeusaert - GCN
James Daly - NID
Keith Woods - COO
Wim Parys - OTH
Arjen Lemmen - VBD
Who are the major shareholders of argenx SE?

Here are the top five shareholders of argenx SE based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.87% (5.03m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.88% (1.98m shares)
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital
Percentage owned: 3.47% (1.77m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.24% (1.65m shares)
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund
Percentage owned: 2.99% (1.52m shares)
Similar to ARGX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.